

FOR RESEARCH USE ONLY

A new dimension of lymph node status evaluation  
in colorectal cancer

## A new dimension of lymph node status evaluation in colorectal cancer


ColoNode accurately detects tumor cell spread and tumor cell aggressiveness in colorectal cancer lymph nodes. The ColoNode test is for research use only and works by providing a quick analysis of a unique set of biomarker mRNAs. ColoNode:

1. objectively detects tumor cells in colorectal cancer (CRC) lymph nodes with high specificity and sensitivity
2. discriminates between aggressive and non-aggressive CRC tumors

After using the ColoNode kit, the ColoNode Software provides a fast and easy calculation of the test results.

ColoNode will give access to a new powerful tool for lymph node evaluation.

### *ColoNode® Software test result summary*



## ColoNode benefits

- Focuses on spread of tumor cells to the lymph nodes - the most important prognostic factor over blood and tumor analysis in CRC.
- Gives an objective, reliable, sensitive and specific assessment of tumor spread.
- Evaluates the aggressiveness of the spread tumor cells - giving scientists a new tool for evaluation of the key risk factor for recurrent colorectal cancer.
- Is fast and readily adaptable for automation.

*The ColoNode kit*



## Market need

Colorectal cancer is the third most common cancer type worldwide with 1.8 million new cases yearly. The primary treatment, surgery, only cures half of the patients. Therefore, there is an urgent need to better diagnose and prognosticate individual patients, so that those at risk for recurrent disease receive postoperative chemotherapy, and patients cured by surgery alone do not undergo unnecessary, complicated and costly treatments in vain.

Cancer cells in adjacent lymph nodes is the most important indicator for patients at risk for recurrent disease. Unfortunately, a considerable number of patients are missed by today's routine clinical method; histopathological microscopic investigation of lymph nodes. The reason is that the method is insensitive (<1% lymph node volume is inspected), and cannot discriminate between aggressive and non-aggressive cancer cells.

As a consequence, many patients today do not receive the most beneficial treatment. This causes unnecessary suffering of the patients and higher health care costs.

## **Clinical studies**

Performed and ongoing studies involving ColoNode:

- Prospective clinical study including 174 CRC patients and control patients. Results showing a comparison between ColoNode biomarker combination and the routine method.<sup>1,2</sup>
- Retrospective clinical study including ~200 formalin fixed lymph nodes. Results showing ColoNode performance on formalin fixed lymph node sections compared to the routine method. Unpublished
- Prospective multicenter clinical study in Sweden (COLONODE study). Inclusion of patients ongoing (goal 325 patients).

All described clinical studies are in collaboration with Umeå University.

## **ColoNode key references**

1. Allocating colorectal cancer patients to different risk categories by using a five-biomarker mRNA combination in lymph node analysis. Olsson L, Hammarström M-L, Israelsson A, Lindmark G, Hammarström, S. PLoS ONE 15(2): e0229007. <https://doi.org/10.1371/journal.pone.0229007>
2. Biomarker mRNAs as prognostic tools for lymph node analysis in colorectal cancer. Hammarström S. Biomark Med. 2019; 13(10): 801-803. Editorial. doi: 10.2217/bmm-2019-0203

**ColoNode reference no:** CN201604

## **About HiloProbe**

HiloProbe is a company in the cancer diagnostic field. ColoNode is based on high quality original research from Umeå University, Norrlands University Hospital and Helsingborg Hospital, Sweden. ColoNode® trademark is owned by HiloProbe.

### **Contact information**

Phone: +46 768216770, E-mail: [info@colonode.se](mailto:info@colonode.se), [www.hiloprobe.se](http://www.hiloprobe.se) and [www.colonode.se](http://www.colonode.se)

**HILOPROBE**